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Partum-related hemorrhage is the leading cause of morbidity
and mortality among pregnant women resulting in 140,000
deaths each year.1 Although the majority of these deaths occur
in low income countries, excessive bleeding at delivery is also
frequent in high resource countries. In Australia, Canada and
the US, 3-7% of deliveries in 2005 were complicated by pri-
mary postpartum hemorrhage.2
The bleeding risk is expected to be higher in women with
inherited thrombocytopenias (ITs) because of low platelet
counts and associated defects of platelet function in some dis-
orders. Nevertheless, few studies have investigated this topic
and there is little evidence to guide management of pregnancy
and delivery.3 Fetal and neonatal outcomes are also not well-
described. 
One of the forms of IT most investigated with respect to
pregnancy is biallelic Bernard-Soulier Syndrome (bBSS), proba-
bly because of its early identification in the middle of the last
century. A systematic review of the literature published in 2010
identified 16 relevant articles, all case reports, describing 30
deliveries in 18 bBSS women.4 Excessive bleeding occurred in
18 cases of which blood transfusion was required in 15. All
women survived, but 2 required emergency hysterectomy.
Concerning the fetus, there was one intra-uterine death caused
by gastrointestinal bleeding and one neonatal death due to
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Pregnancy in women with inherited thrombocytopenias is a major matter of concern as both the mothers and the
newborns are potentially at risk of bleeding. However, medical management of this condition cannot be based on
evidence because of the lack of consistent information in the literature. To advance knowledge on this matter, we
performed a multicentric, retrospective study evaluating 339 pregnancies in 181 women with 13 different forms of
inherited thrombocytopenia. Neither the degree of thrombocytopenia nor the severity of bleeding tendency wors-
ened during pregnancy and the course of pregnancy did not differ from that of healthy subjects in terms of miscar-
riages, fetal bleeding and pre-term births. The degree of thrombocytopenia in the babies was similar to that in the
mother. Only 7 of 156 affected newborns had delivery-related bleeding, but 2 of them died of cerebral hemorrhage.
The frequency of delivery-related maternal bleeding ranged from 6.8% to 14.2% depending on the definition of
abnormal blood loss, suggesting that the risk of abnormal blood loss was increased with respect to the general pop-
ulation. However, no mother died or had to undergo hysterectomy to arrest bleeding. The search for parameters
predicting delivery-related bleeding in the mother suggested that hemorrhages requiring blood transfusion were
more frequent in women with history of severe bleedings before pregnancy and with platelet count at delivery
below 50 x 109/L.   
Analysis of 339 pregnancies in 181 women with 13 different 
forms of inherited thrombocytopenia
Patrizia Noris,1 Nicole Schlegel,2 Catherine Klersy,3 Paula G. Heller,4 Elisa Civaschi,1 Nuria Pujol-Moix,5 Fabrizio Fabris,6
Remi Favier,7,8 Paolo Gresele,9 Véronique Latger-Cannard,10,11 Adam Cuker,12 Paquita Nurden,13 Andreas Greinacher,14
Marco Cattaneo,15 Erica De Candia,16 Alessandro Pecci,1 Marie-Françoise Hurtaud-Roux,2 Ana C. Glembotsky,4
Eduardo Muñiz-Diaz,17 Maria Luigia Randi,6 Nathalie Trillot,18 Loredana Bury,9 Thomas Lecompte,19,20
Caterina Marconi,21 Anna Savoia,22,23 and Carlo L. Balduini1 on behalf of the European Hematology Association –
Scientific Working Group on Thrombocytopenias and Platelet Function Disorders
1Department of Internal Medicine, University of Pavia-IRCCS Policlinico San Matteo Foundation, Italy; 2National Reference Centre on
Inherited Platelet Disorders and Service d’Hématologie Biologique, CHU Robert Debré and Paris 7 Denis Diderot University, Paris,
France; 3Service of Biometry and Statistics, IRCCS Policlinico San Matteo Foundation, Pavia, Italy; 4Institute of Medical Research Alfredo
Lanari, University of Buenos Aires, Argentina; 5Universitat Autònoma de Barcelona, Institut de Recerca Biomèdica Sant Pau, Spain;
6Department of Medicine-DIMED, University of Padova Medical School, Italy; 7AP-HP, Armand Trousseau Children’s Hospital,
Haematological Laboratory, French Reference Center for Inherited Platelet disorders, Paris, France; 8Inserm UMR1009, Villejuif, France;
9Department of Internal Medicine, University of Perugia, Italy;  10Centre de Compétence Nord-Est des Pathologies Plaquettaires from the
frame of the Reference French Centre, France; 11Service d’Hématologie Biologique, Centre Hospitalo-Universitaire, Nancy, France;
12Department of Medicine and Department of Pathology & Laboratory Medicine, Perelman School of Medicine, University of
Pennsylvania, Philadelphia, PA, USA; 13Plateforme Technologique et d’Innovation Biomédicale, Hôpital Xavier Arnozan, Pessac, France;
14Institut für Immunologie und Transfusionsmedizin, Greifswald, Germany; 15Medicina III, Ospedale San Paolo, Dipartimento di Scienze
della Salute, Università degli Studi di Milano, Italy; 16Servizio Malattie Emorragiche e Trombotiche, Istituto di Medicina Interna e
Geriatria, Policlinico Agostino Gemelli, Università Cattolica del Sacro Cuore, Roma, Italy; 17Immunohematology Department,  Banc de
Sang i Teixits de Catalunya, Barcelona, Spain; 18Institut d’Hématologie-Transfusion, Pôle Biologie Pathologie Génétique, CHRU, Lille,
France; 19Département des Spécialités de Médecine, Service d’Hématologie, Hôpitaux Universitaires de Genève, Suisse; 20Université de
Genève, Faculté de Médecine, Suisse; 21Genetica Medica, Dipartimento di Scienze Mediche Chirurgiche, Policlinico Sant'Orsola-Malpighi,
University of Bologna, Italy; 22Department of Medical Sciences, University of Trieste, Italy; and 23Institute for Maternal and Child Health –
IRCCS Burlo Garofolo, Trieste, Italy
ABSTRACT
antepartum intracranial hemorrhage. On this basis, it has
been concluded that bBSS is associated with a very high risk
of serious bleeding in the mother and the neonate.
Some information on pregnancy outcome is available
also for MYH9-related disease (MYH9-RD), one of the most
frequent forms of IT. A recent review of the literature exam-
ined 25 case reports and one case series describing a total of
75 pregnancies in 40 women.5 Postpartum hemorrhage in
the mother occurred in 4 cases, while no obvious bleeding
complications were reported among the newborns. Based
on these data, MYH9-RD does not seem to increase bleed-
ing risk either in mothers or neonates.
Limited data on pregnancy outcomes have been provided
for patients with mild to moderate thrombocytopenia due
to monoallelic BSS (mBSS), in all cases induced by the
p.Ala156Val substitution in GPIb alpha (Bolzano mutation).6
Overall, 20 women delivered 34 children with no excessive
maternal or neonatal bleeding. Although the authors did
not provide information on management of pregnancies
and childbirths, this study suggests that women with mBSS
have gestational outcomes similar to healthy subjects.
A moderate risk of bleeding during delivery has been
reported in a series of subjects with thrombocytopenia
induced by ANKRD26 mutations (ANKRD26-related
thrombocytopenia, ANKRD26-RT).7 Thirteen patients gave
birth, either vaginally or by caesarean section, with bleed-
ing complications in 3 women. No information was provid-
ed on prophylactic treatment or neonatal outcomes.
The paucity of evidence presently available, therefore,
indicates that maternal and neonatal bleeding risk during
pregnancy and delivery may vary with different forms of
IT, ranging from very severe to very mild. However, the evi-
dence concerns only four ITs and largely derives from case
reports or series of patients not specifically investigated
with respect to pregnancy. 
To remedy this scarcity of information, we performed a
retrospective, multicentric study aimed at systematically
collecting and analyzing pregnancy outcomes in a large
series of patients with well-defined forms of IT.
Methods
Patients
This study was promoted by the Scientific Working Group on
Thrombocytopenias and Platelet Function Disorders of the
European Hematology Association (EHA) and was announced at
the 2013 EHA Congress in Stockholm. Clinical centers that, based
on scientific publications and/or personal knowledge, represent
points of reference for ITs were invited to participate. Forty-five
institutions took part in the study. They were asked to analyze
their databases and extract data on pregnancies in women with
ITs. A series of questions had to be answered for each enrolled case
related to the base-line characteristics of the mother, the course of
pregnancy, and the management and outcome of delivery, with
particular attention to the bleeding events in the mother and the
newborn. 
Only women with diagnoses confirmed by genetic analysis
were eligible for the study. As an exception, positivity of the
immunofluorescence test for MYH9-related disease (MYH9-RD)
was considered sufficient for making the diagnosis in patients
where mutational screening was not available because of its very
high sensitivity and specificity.8
Neonates for whom genetic screening was not available were
considered affected from the same illness as the mother whenever
they were thrombocytopenic and the mother had a dominant dis-
order. In case of recessive disorders, documentation that the par-
ents were carriers of the disease was required. 
The Institutional Review Board of the IRCCS Policlinico San
Matteo Foundation of Pavia, Italy, approved the study protocol.
The study was performed in accordance with the Declaration of
Helsinki, and each center complied with local ethical rules.
Classification of bleeding
Because of the retrospective nature of the study, it was not pos-
sible to use the most recent bleeding scores that are most suited to
patients with primary hemostasis defects. Spontaneous bleeding
tendency in the mother before pregnancy was, therefore measured
by the World Health Organization bleeding scale: grade 0 indicates
no bleeding; grade 1, petechiae; grade 2, mild blood loss; grade 3,
gross blood loss; grade 4, debilitating blood loss.9
The amount of blood loss has been used by most authors to
identify post-partum hemorrhages.10 However, this parameter was
available for only a few patients, and we could not use it.
Therefore, we identified two definitions for excessive bleeding at
delivery: “excessive bleedings requiring blood transfusion” (EBBT),
based on transfusion of platelets and/or red blood cells during or
after delivery to treat bleeding (prophylactic platelet transfusions
prior to delivery were not considered for definition of EBBT), and
“all excessive bleedings” (AEB), which includes not only patients
receiving platelets and/or red blood cells, but also subjects who did
not receive blood products and were judged by the treating physi-
cian as presenting larger than normal blood loss. Thus, EBBT is a
narrow definition that is expected to identify the most serious
blood loss, while AEB is a broader definition that also encompasses
less severe bleedings.
The same criteria were used to define increased bleedings with
previous surgery. Any type of bleeding in newborns was consid-
ered abnormal and recorded. Miscarriage was defined as sponta-
neous expulsion from the uterus of the products of conception
before viability. Pre-term birth was defined as live birth of a
neonate of less than 37 weeks gestational age. Platelet count was
measured by cell counters available in each center. 
Statistical analysis
Data were described as median and 25th-75th percentiles if contin-
uous and as counts if categorical. EBBT and AEB incidence and
95% confidence intervals (95%CI) were computed. Generalized
linear regression models were used to compare platelet counts
between and within groups; Huber-White robust standard errors
were calculated to account for intra-patient correlation. Logistic
regression was used to assess the association of a series of patients’
characteristics with bleeding; Odds Ratios (OR) and 95%CI were
computed. ROC curve analysis was used to identify the optimal
cut offs for the association of platelets counts and bleedings. Stata
13 (StataCorp, College Station, TX, USA) was used for computa-
tion. Two-sided P<0.05 was considered statistically significant.
Results
Not all data were available for all investigated patients,
and results described below report the number of investi-
gated cases for which data were available. In case the num-
ber of investigated patients is not reported, it is intended
that all patients were studied.
Womens’ base-line characteristics 
One hundred and eighty-one women with 13 different
forms of IT who had a total of 339 pregnancies were inves-
tigated retrospectively by 45 centers in 20 countries. In 169
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Table 1. Diagnosis and base-line features of investigated women with different forms of inherited thrombocytopenia who had one or more pregnancies. 
Disorder N. of Median N. of patients with a Median platelet WHO bleeding N. of N. of N. of N. of 
(abb., women age in years previous diagnosis/count before pregnancy scale*, N. patients patients patients patients
phenotype at diagnosis, medical treatment/ x109/L, 25th-75th of patients with a receiving receiving with EBBT with AEB 
MIM number) 25th-75th percentile splenectomy for percentile history of spontaneous surgery prophylactic at surgery at surgery
immune bleeding of grades platelet N. of  evaluated N. of 
thrombocytopenia 0-1-2-3-4 transfusions patients evaluated
N. of  evaluated evaluated
patients
MYH9-related 98 31, 19-42 41/32/11 40, 23-64 39-21-30-5-3 67 26 (67) 9 (67) 20 (67)
disease  
(MYH9-RD, 600208) 
ANKRD26-related 23 21, 11-40 8/6/3 54, 30-84 6-4-7-3-3 12 2 (11) 0 (11) 1 (11)
thrombocytopenia 
(ANKRD26-RT, 188000)
Biallelic 13 33, 26-36 3/3/1 50, 23-92 5-0-5-2-1 8 1 (7) 1 (7) 2 (7)
Bernard-Soulier 
syndrome (bBSS, 231200)
Monoallelic 24 31, 19-41 1/1/0 86, 77-111 12-4-3-5-0 13 1 (13) 0 (13) 3 (13)
Bernard-Soulier syndrome 
(mBSS, 231200)
ACTN1-related 9 21, 17-40 0/0/0 77, 65-94 2-3-2-2-0 4 0 (4) 0 (4) 2 (4)
thrombocytopenia
(ACTN1-RT, 615193)
Familial platelet 4 37, 26-38 1/1/0 116, 93-138 0-0-3-0-1 2 0 (2) 0 (2) 1 (2)
disorder and 
predisposition 
to acute myelogenous leukemia 
(FPD/AML, 601399)
ITGB3-related 3 16, 11-37 0/0/0 78, 65-114 1-0-0-2-0 3 3 (3) 0 (3) 0 (3)
thrombocytopenia 
(ITGB3-RT, 187800)
Platelet-type 2 27, 27-28 1/0/0 80, 30-130 0-1-0-0-1 1 0 (1) 0 (1) 1 (1)
von Willebrand disease 
(VWDP, 177820)
Gray platelet 1 13 1/1/0 65 0-0-0-1-0 1 1 (1) 0 (1) 0 (1)
syndrome 
(GPS, 139090)
FLNA-related 1 23 0/0/0 43 1-0-0-0-0 1 0 (1) 0 (1) 0 (1)
thrombocytopenia 
(FLNA-RT, nd)
TUBB1-related 1 4 1/0/0 100 0-1-0-0-0 1 0 (1) 0 (1)
thrombocytopenia
(TUBB1-RT, 613112) 0 (1)
Velocardiofacial 1 34 0/0/0 75 0-1-0-0-0 1 0 (1) 0 (1) 0 (1)
syndrome 
(VCFS, 192430)
CYCS-related 1 25 0/0/0 35 0-1-0-0-0 1 0 (1) 0 (1) 0 (1)
thrombocytopenia  
(CYCS-RT, 612004)
Total 181 29 (19-39) 57/44/15 57 (30-82) 66-36-50-20-9 114 34 (112) 10 (112) 30 (112)
*World Health Organization bleeding scale:  grade 0, no bleeding; grade 1, petechiae; grade 2, mild blood loss; grade 3, gross blood loss; grade 4, debilitating blood loss;  EBBT: excessive bleeding
requiring blood transfusion; AEB: all excessive bleedings; 25th-75th: 25th-75th percentiles.
women, diagnoses were confirmed by the identification of
mutations in the candidate genes, while in 12 subjects a
diagnosis of MYH9-RD was made on the basis of a positive
immunofluorescence test for the distribution of MYH9 pro-
tein in neutrophils.8 Of note, 18 of 24 women with the diag-
nosis of mBSS had the p.Ala156Val substitution in GPIb
alpha (Bolzano mutation).6
Patients’ features before pregnancy are reported in Table
1. A feature common to many investigated patients was the
difficulty of making a correct diagnosis of IT, as shown by
the observation that 57 subjects were initially misdiagnosed
with immune thrombocytopenia. Forty-four of these
women received unnecessary treatment, including splenec-
tomy in 15 cases. Difficulties in diagnosis is also demon-
strated by the finding that the inherited origin of thrombo-
cytopenia was recognized in adulthood in most cases, with
a mean age at diagnosis of 30 years. These findings under-
score the need to maintain a high index of suspicion for ITs
in the evaluation of patients with thrombocytopenia.11
Thrombocytopenia was on average moderate, with a
mean platelet count of 60 x 109/L in the whole case series
and a mean platelet count higher than 45 x 109/L in all dis-
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orders for which more than one patient was examined.
However, severely reduced platelet counts were observed
in a few cases. In this regard, it is important to note that
platelet counts were measured by electronic cell counters
and that these instruments are known not to recognize very
large platelets.12 It is, therefore, expected that the degree of
thrombocytopenia was overestimated in patients with
inherited macrothrombocytopenias, especially those with
MYH9-RD and bBSS who typically have giant platelets.
Spontaneous bleeding tendency before pregnancy was on
average mild. WHO grade 3 and 4 bleeding were reported
in only 20 and 9 of 181 subjects, respectively. 
Perioperative AEB and EBBT were reported in 30 and 10
of 112 women receiving surgery, respectively.
Gestations
No variation in severity of the pre-existing bleeding ten-
dency was reported during pregnancy (data not shown). 
The course of gestation was uneventful in 304 cases,
while miscarriage was reported in 34 pregnancies (10.1%,
95%CI: 7.2-14.0). One therapeutic interruption of pregnan-
cy because of fetal malformation was reported. The inci-
dence of miscarriage is superimposable to that observed in
a large population of white women in the US (10.2%).13
Pregnancy loss occurred in the first trimester in 29 cases, in
the second in 5 cases, and in the third in one case. 
Pre-term birth was recorded for 30 pregnancies (9.9%,
95%CI: 6.8-13.7), and thus the frequency of this event was
not significantly different from that observed in a general
population of Western countries (7.4%).14 All pre-term
deliveries occurred at a gestational age of 36 or 37 weeks.
Newborns
Diagnostic definition was possible in 278 newborns: 156
were affected by ITs, while 122 were unaffected.
Comparison of platelet counts in the 126 affected new-
borns for which this information was available with base-
line platelet counts in their mothers revealed that the degree
of thrombocytopenia was similar, although the small
observed difference was statistically significant (mean
platelet count in the newborns 69 x 109 platelets/L, in the
mothers 58 x 109/L; P=0.020).
Bleeding signs consisting of petechiae were observed in 5
affected neonates, while fatal cerebral hemorrhages were
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Table 2. Characteristics of pregnancy,  delivery and newborns in women with inherited thrombocytopenias. The number of investigated patients is reported (in
brackets) in case of missing data.
Disorders N. of Median Median N. of term/ N. of vaginal N. of N. of N. of N. of N. of N. of 
pregnancies/ age in platelet preterm deliveries/ deliveries with  deliveries withdeliveries with deliveries with healthy affected
miscarriages years at count at deliveries cesarean general/ prophylactic EBBT, % AEB, % newborns newborns
delivery,  delivery (N. of sections spinal  or platelet incidence, CI incidence, CI affected by with
25th-75th x109/L, evaluated (N. of epidural/no transfusion (N. of (N. of the mother bleedings 
percentile 25th-75th deliveries) evaluated anesthesia (N. of evaluated evaluated disorder (N. of 
percentile deliveries) (N. of evaluated deliveries) deliveries) (N. of evaluated 
(N. of evaluated deliveries) evaluated babies)
evaluated deliveries) babies)
deliveries)
MYH9-RD 185/21 28, 24-32 60, 34-80 142/20 94/69 54/34/73 31 13, 8.3, 4.5- 24, 15.3, 10.1-22 58/94 6 (94)
(86) (162) (163) (163) (161) 13.8 (156) (156) (152)
ANKRD26-RT 48/6 29, 25-30 34, 28-76 41/1 27/15 5/2/27 4 3, 7.1, 1.4- 5, 11.9, 17/23 0 (23)
(26) (42) (42) (34) (42) 19.4  (42) 3.9-25.6 (42) (40)
bBSS 22/1 32, 28-35 40, 26-65 16/5 8/13 9/4/7 6 1, 4.7, 0.1-23.8  3, 14.2, 3-36.3 12/3 (15) 0 (3)
(15) (21) (21) (20) (21) (21) (21)
mBSS 42/3 29, 25-34 86, 66-105 37/2 29/10 6/4/28 0 1, 2.5, 0.1-13.4 5, 12.8, 4.2- 19/18 1(18)
(33) (39) (39) (38) (39) (39) 27.4 (39) (37)
ACTN1-RT 18/1 24, 22-26 72, 55-88 17/0 17/0 0/0/17 0 0, 0, 0-19.5 0, 0, 0-19.5 6/11 0 (11)
(11) (17) (17) (17) (17) (17) (17)
FPD/AML 9/2 27, 21-29 92, 80-105 7/0 4/3 0/1/4 1 1, 14.2, 0.3- 1, 14.2, 0.3- 3/3 0(3)
(4) (7) (7) (5) (7) 57.8 (7) 57.8 (7) (6)
ITGB3-RT 3/0 28, 24-29 82, 58-110 (3) 3/0 (3) 0/3 (3) 1/0/0 (1) 2 (3) 0, 0, 0-70.7 (3) 0, 0, 0-70.7 (3) 1/2 (3) 0 (2)
VWDP 5/0 30, 29-32 110, 58-113 (5) 4/1 (5) 3/2 (5) 2/0/3 (5) 0 (5) 1, 20, 0.5-71.6 (5)3, 60, 14.6-94.7 (5) 3/0 (3) 0 (0)
GPS 3/1 25, 25-28 47, 40-55 (2) 2/0 (2) 2/0 (2) 2/0/0 (2) 2 (2) 0, 0, 0-84.1 (2) 1, 50, 1.2-98.7 (2) 2/0 (2) 0 (0)
FLNA-RT 1/0 28 82 (1) 1/0 (1) 1/0 (1) 0/0/1 (1) 0 (1) 0, 0, 0-97.5  (1) 0, 0, 0-97.5 0/1 (1) 0 (1)
(1) (1)
TUBB1-RT 1/0 39 48 (1) 0/1 (1) 0/1 (1) 1/0/0 (1) 0 (1) 0, 0, 0-97.5 (1) 0, 0, 0-97.5 (1) 0/0 (0) 0 (0)
VCFS 1/0 33 (0) 1/0 (1) 1/0 (1) 0/1/0 (1) 0 (1) 0, 0, 0-97.5 (1) 0, 0, 0-97.5 (1) 0/1 (1) 0 (1)
CYSC-RT 1/0 28 50 (1) 1/0 (1) 1/0 (1) 0/0/1 (1) 0 (1) 0, 0, 0-97.5 (1) 0, 0, 0-97.5 (1) 1/0 (1) 0 (0)
TOTAL 339/35 28, 25-32 65, 37-85 272/30 187/116 80/46/161 46 (301) 20, 6.7, 4.1- 42, 14.1, 10.4- 122/156 () 7 (156)
(188) (302) (303) (289) 10.2 (296) 18.6 (296) 278
EBBT: excessive bleeding requiring blood transfusion; AEB: all excessive bleedings; 25th-75th: 25th-75th percentiles; CI: 95% confidence intervals.
reported in 2 infants born by vaginal delivery to 2 MYH9-
RD mothers with greatly reduced platelet counts (12 and 16
x 109/L, respectively). Platelet count was severely reduced in
one newborn (7 x 109/L) with the same MYH9mutation as
the mother, while neither testing for MYH9-RD nor a
platelet count were carried out in the other neonate because
he died shortly after birth.
Deliveries 
Table 2 describes maternal characteristics at delivery as
well as management of childbirth and bleeding events.
Platelet count at delivery was available in 188 cases, and
comparison with base-line non-pregnant platelet count
revealed mild differences (mean platelet count before preg-
nancy 56 x 109/L, at delivery 65 x 109/L; P=0.071). Thus,
only limited changes in platelet count are expected to occur
during pregnancy in patients with ITs. 
Prophylactic platelet transfusions were given in prepara-
tion for delivery in 46 of 301 evaluable cases, while other
prophylactic treatments, consisting of steroids, desmo-
pressin, tranexamic acid or recombinant activated factor
VII, were given in 9, 5, 2 and one case, respectively. 
Mean platelet count at delivery was lower in women
given prophylactic platelet transfusions than in women not
receiving this treatment (40 vs. 69 x 109/L; P<0.001). Similar
results were obtained when baseline non-pregnant platelets
counts were considered (38 vs. 65 x 109/L; P<0.001). This
indicates that platelet count may have been a parameter
used by physicians to determine the need for prophylactic
platelet transfusion. 
One hundred and sixteen of 303 births were by caesarean
section. In the 289 deliveries for which information on pain
control was available, general anesthesia was performed in
80 cases (27.7%), and spinal or epidural anesthesia in 46
(15.9%). No bleeding complications related to these proce-
dures were reported. 
AEB occurred in 42 cases (14.2% of deliveries, 95%CI:
10.4-18.7) and EBBT in 20 cases (6.8% of deliveries, 95%CI:
4.17-10.2). In case of EBBT, platelet transfusions were given
in 6 deliveries, red cell transfusions in 9 and both red blood
cell and platelet concentrates in 5. Since the incidence of
abnormal bleeding at delivery in the normal population, as
evaluated by the amount of blood loss, is 3-7% in high
resource countries,2 the frequency of AEB appears to be
higher in ITs than in the general population. Comparison of
the need for red blood cell transfusion in our case series is
possible with that observed in the general population: fif-
teen deliveries in women with ITs required erythrocyte
transfusions (5.06%, 95%CI: 2.8-8.0), while the need for
this treatment ranged from 0.5 to 1.2% in non-thrombocy-
topenic women.2,15,16 Altogether, these results indicate that
bleeding risk at delivery is increased in ITs.
No women died from complications of childbirth or
required hysterectomy to stop bleeding. 
Correlations between mothers’ features and bleedings
at delivery
Some predictors of AEB and EBBT at delivery were iden-
tified (Table 3). Considering EBBT at delivery, a trend
towards statistically significant association was found with
EBBT at previous surgery (OR 4.7, 95%CI: 0.8-26.9), while
a significant correlation was found with a history of grade
3 or 4 (OR 5.32, 95%CI: 1.22-23.11) and grade 4 (OR 24.50,
95%CI: 4.75-126.41) of WHO bleeding scale. 
EBBT was also significantly associated with a base-line
platelet count in the lowest tertile, and a trend towards sig-
nificance was found between EBBT and platelet count in
the lowest tertile at delivery (platelets >49 x 109/L). ROC
analysis identified platelet counts of 44 and 50 x 109/L as the
optimal cut offs of platelet counts before pregnancy and at
delivery, respectively, for the identification of patients with
a higher risk for EBBT. The incidence of EBBT in mothers
with platelet counts below these cut-off values before preg-
nancy and at delivery was 3.92 (95%CI: 1.43-10.70) and
7.61 (95%CI: 1.55-37.60) times higher, respectively, than in
patients with higher platelet counts. Both differences were
statistically significant. 
EBBT was not less frequent in vaginal deliveries than in
caesarean sections and was not reduced in women who
received prophylactic platelet transfusions prior to delivery.
Table 2 shows that the incidence of bleeding requiring
blood transfusion was not significantly different in different
forms of IT. However, this finding is reliable for MYH9-RD,
ANKRD6-RT, bBSS, mBSS and ACTN1-related thrombocy-
topenia (ACTN1-RT) because of the high number of inves-
tigated deliveries, while it is not dependable for all other
disorders because of the low number of observed child-
births.
A history of surgical bleeding and lower platelet counts
also correlated with AEB, though to a lesser extent than
with EBBT. As with EBBT, other examined maternal char-
acteristics did not predict AEB at delivery. 
Discussion
Inherited thrombocytopenias have long been considered
exceedingly rare, but recent advances have facilitated diag-
nosis and greatly increased the number of reported
patients.17 Although population studies have not yet been
performed, it has recently been calculated that the preva-
lence of ITs in Italy is at least 2.7 in 100,000.18 The improved
knowledge of ITs has also changed our view of their clinical
picture. It has been shown that bleeding tendency is mild in
the majority of patients and spontaneous life-threatening
hemorrhage is uncommon/rare.11 Nevertheless, hemostatic
challenges always need careful attention. Pregnancy and
delivery are especially critical because both mothers and
affected newborns are at risk of hemorrhage. However,
published data are insufficient to provide an evidence-based
approach to management during pregnancy and delivery.
The present study on 339 pregnancies in 181 women with
13 different ITs provides, for the first time, the opportunity
to systematically examine this topic in detail.
Results of our study on the one hand suggest that the
course of pregnancy in ITs does not differ from that of
healthy women; on the other hand, the risk of bleeding
with childbirth appears to be increased in both mothers and
neonates.
Neither thrombocytopenia nor bleeding tendency wors-
ened during pregnancy. The incidence of pregnancy loss
was superimposable to that observed in healthy women,
and the incidence of pre-term birth was not increased in
women with ITs. No intrauterine bleeding was reported in
the 156 fetuses who inherited IT. However, antepartum
gastrointestinal19 and intracranial bleedings20 with fatal con-
sequences have been previously described in the fetuses of
2 bBSS mothers. A risk of major bleeding in utero must,
therefore, be borne in mind, though such events were not
observed in our study cohort. Regarding delivery-related
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neonatal bleedings, our data indicate that the risk is low,
although fatal hemorrhages may occur. Indeed, only 7 of
156 affected newborns had bleeding. In 5 cases, bleeding
consisted of petechiae, but 2 neonates, both born by vaginal
delivery to mothers with severe thrombocytopenia due to
MYH9-RD, died of cerebral hemorrhage. To our knowl-
edge, delivery-related fatal intracranial hemorrhages have
not been previously reported in neonates with ITs. The
small number of neonates affected by ITs other than
MYH9-RD does not allow us to exclude a risk of severe
neonatal hemorrhage with these conditions, though none
were observed in our series. Similarly, we cannot conclude
that vaginal delivery is associated with a greater risk of
neonatal hemorrhage, because this type of birth was chosen
in the vast majority of MYH9-RD women, as well as in
other forms of ITs. Thus, infants delivered vaginally by
severely thrombocytopenic women with MYH9-RD must
be considered at risk for intracranial bleeding; we cannot
exclude the possibility that other forms of IT or caesarean
section may expose newborns to similar risk. The incidence
of delivery-related maternal bleeding in our case series
ranged from 6.8% to 14.2% depending on the criterion
used for defining abnormal bleeding. Comparison with
healthy women is difficult, because most commonly used
definitions of partum-related hemorrhages in the general
population rely on the amount of blood loss (>500 mL for
vaginal deliveries, and >750-1500 mL for caesarean births),2
but this information was not available for the majority of
our patients. Instead, we adopted two different criteria for
increased bleeding: one based on the need to give blood
products (EBBT), the other taking into account not only
blood transfusions, but also the judgment of the obstetri-
cian that bleeding was excessive (AEB). The former defini-
tion may underestimate the occurrence of hemorrhages as
defined by the entity of blood loss, because it is conceivable
that not all women losing more than 500 mL of blood after
vaginal delivery or more than 750 mL after caesarean sec-
tion received blood transfusions. Also the latter definition
risks underestimating the frequency of bleedings because it
includes a subjective assessment and it has been shown that
P. Noris et al.
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Table 3. Correlations between mother characteristics and bleeding at delivery.
Mothers’ characteristics N.  of EBBT at delivery AEB at delivery
deliveries Events OR 95% CI P-value Events OR 95% CI P-value
EBBT at previous surgery 17 4 4.77 0.85-26.87 0.08 6 1.45 0.36-5.83 0.60
AEB at previous surgery 56 6 2.06 0.69-6.12 0.20 15 2.75 1.15-6.62 0.023
Tertiles of WHO bleeding scale* 0.08 0.31
1st (0-0) 101 3 1 - - 11 1 - -
2nd (1-2) 145 10 2.42 0.65-8.96 0.19 20 1.31 0.53-3.21 0.56
3rd (3-4) 50 7 5.32 1.22-23.11 0.026 11 2.31 0.77-6.97 0.13
WHO bleeding scale* <0.001 0.06
0 101 3 1 - - 11 1 - -
1 59 2 1.15 0.19-7.06 0.88 6 0.93 0.30-2.83 0.30
2 86 8 3.35 0.87-12.92 0.08 14 1.59 0.60-4.20 0.60
3 36 1 0.93 0.09-9.20 0.95 4 1.02 0.29-3.61 0.97
4 14 6 24.50 4.75-126.41 <0.001 7 8.18 1.80-37.29 0.007
Tertiles of platelet count at delivery 0.09 0.40
1st (<49 x 109/L) 65 7 1 - - 11 1 - -
2nd (49-80 x 109/L) 66 1 0.12 0.01-1.29 0.080 6 0.13 0.01-1.09 0.06
3rd (> 80 x 109/L) 56 2 0.28 0.04-2.00 0.20 8 0.31 0.06-1.54 0.15
Tertiles of platelet count before pregnancy 0.11 0.60
1st (<39 x 109/L) 101 10 1 - - 17 1 - -
2nd (39-77 x 109/L) 96 8 0.83 0.30-2.27 0.71 14 0.84 0.36-1.96 0.69
3rd (>77 x 109/L) 99 2 0.19 0.04-0.90 0.037 11 0.62 0.24-1.59 0.31
Platelet count before 117 14 3.92 1.43-10.70 0.008 23 2.06 0.99-4.28 0.053
pregnancy < 44 x 109/L
Platelet count at delivery 69 8 7.61 1.55-37.60 0.012 14 2.49 1.02-6.02 0.046
< 50 x 109/L 
Diagnosis of biallelic 21 1 0.67 0.08-5.58 0.71 3 1.01 0.29-3.47 1.00
Bernard-Soulier syndrome
Primipara 168 14 1.85 0.71-4.84 0.21 27 1.44 0.79-2.63 0.23
Tertiles of age at pregnancy 0.81 0.31
1st (15-26) 102 8 1 - - 18 1 - -
2nd (27-31) 103 7 0.86 0.33-2.26 0.75 15 0.80 0.35-1.80 0.58
3rd (32-41) 91 5 0.68 0.22-2.15 0.51 9 0.51 0.22-1.21 0.12
Prophylactic platelet 44 3 1.01 0.30-3.42 0.99 8 1.47 0.62-3.49 0.38
transfusion before delivery
Vaginal delivery 183 11 0.74 0.31-1.79 0.50 25 0.89 0.44-1.83 0.76
*World Health Organization bleeding scale: grade 0, no bleeding; grade 1, petechiae; grade 2, mild blood loss; grade 3, gross blood loss; grade 4, debilitating blood loss; EBBT: excessive bleed-
ing requiring blood transfusion; AEB: all excessive bleedings; OR: Odds Ratio; CI: confidence intervals. 
visual estimation tends to under-evaluate blood loss at
delivery with respect to more accurate measurements.21
Since the incidence of increased bleeding at delivery in the
general population ranges from 3% to 7%,2 AEB in our case
series was higher than normal, while EBBT was at the
upper limit of normal range. However, the observation that
red blood cell transfusions at delivery were given much
more frequently in our patients (5% of deliveries) than in
the general population (0.5-1.2%) strongly suggests that
bleeding risk is increased in ITs.  
Because of this, we searched for mothers’ parameters able
to predict delivery-related bleedings. EBBT at childbirth
was more frequent in women with higher grades of the
WHO bleeding scale before pregnancy, and a trend toward
statistical significance was found between EBBT at delivery
and EBBT at previous surgeries. Also the degree of throm-
bocytopenia before pregnancy and at delivery was related
to EBBT, although with different degrees of statistical signif-
icance. Based on this finding, we searched for the cut-off
value of platelet count able to predict EBBT by ROC curve
analysis, and found that platelet count less than 50 x 109/L
at delivery and less than 44 x 109/L before pregnancy were
significantly associated with higher frequency of hemor-
rhage requiring blood products. Thus, the bleeding tenden-
cy before pregnancy and the degree of thrombocytopenia
are both important to predict severe bleeding at childbirth.
Of note, experts’ recommendations for management of
pregnancy in patients with immune thrombocytopenia
identified platelet count 50 x 109/L as the minimum value
required for safe delivery.22,23
Broadly similar results were obtained in the search for
correlations between AEB at delivery in the mothers and
their previous bleeding tendency as well as their platelet
counts. However, the risk deriving from unfavorable fea-
tures was lower and had lower statistical significance than
for EBBT, probably because the definition of AEB includes
a subjective judgment of milder bleeding events.
No other investigated maternal characteristics predicted
increased bleeding at delivery. Based on the common
notion that severe hemorrhages are frequent on the occa-
sion of hemostatic challenges in patients with bBSS and the
previously published data on delivery in these patients,4 it is
surprising that bleeding events at childbirth in our case
series were no more frequent in bBSS than in other forms
of IT. This unexpected finding could have several explana-
tions. First, the base-line bleeding tendency in our bBSS
women was milder than that observed in other series of
unselected bBSS patients, as shown by the observation that
WHO grade 3 and 4 bleeding were reported only in 3 of our
13 women, while they were described in 7 of 10 patients of
a previous case series.24 It may be that our group of bBSS
patients was enriched in forms with mild bleeding tenden-
cy because some women with severe bBSS have undergone
hysterectomy for heavy menstruation or have been discour-
aged from having a pregnancy by the fear of bleeding at
delivery. Moreover, the frequency of prophylactic platelet
transfusions in bBSS women was twice that of women
with other ITs, and this may have masked a higher risk of
bleeding. The observation that only one AEB (not requiring
blood products) was reported in 15 deliveries of bBSS
patients not preceded by prophylactic platelet transfusions
supports the hypothesis that giving platelets in preparation
for delivery may be unnecessary in women with mild
forms of bBSS. Finally, the previous systematic review,
which was based on case reports and, therefore, was highly
susceptible to reporting bias, could have overestimated
bleeding risk at delivery. 
Another surprising finding was the similar incidence of
increased bleeding at delivery in mothers receiving or not
receiving prophylactic platelet transfusions, in that this
result might suggest that platelet transfusions were ineffec-
tive. However, the observation that platelet count was
lower in women given transfusions provides a credible
alternative explanation and suggests that prophylactic
platelet infusions were effective in reducing the incidence of
hemorrhage.
Our study has some limitations. First, only a small num-
ber of eligible patients with some forms of IT were identi-
fied by the participating centers (Table 1), likely reflecting
the rarity of these disorders. Creation of larger international
registries is required to further improve knowledge of preg-
nancy outcomes in these rare disorders. Another limitation
derives from the failure of automated cell counters to iden-
tify very large platelets and the resulting underestimation of
platelet count in inherited macrothrombocytopenias, espe-
cially bBSS and MYH9-RD.12 It is thus likely that the degree
of thrombocytopenia in these conditions was overestimat-
ed in our study. Moreover, data were missing in a relevant
number of patients enrolled in the study, a limitation inher-
ent to retrospective investigations. Finally, we compared
the outcome of pregnancy in women with ITs with that
reported in general population. Comparison with non-
thrombocytopenic women from these same institutions
from the same time periods would be more appropriate,
but obtaining the required information from 45 centers in
20 countries seemed to us a hopeless undertaking.
In conclusion, our study showed that delivery-related
bleeding risk is higher in ITs than in the general population
for both mothers, who may have blood loss requiring blood
transfusions, and affected newborns, who may rarely pres-
ent with fatal intracranial hemorrhage. Nevertheless, deliv-
ery occurs without bleeding complications in the vast
majority of mothers and neonates. Our study also identified
the degree of thrombocytopenia and a history of severe
bleeding tendency in the mother as potentially useful
parameters to predict the risk of delivery-related bleedings.  
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